

OriGene Technologies Inc.


9620 Medical Center Drive, Ste 200 Rockville, MD 20850 UNITED STATES Phone: +1-858-888-7900 Fax: +1-858-888-7904 <u>US-info@acris-antibodies.com</u>

PA1195 OriGene EU

Acris Antibodies GmbH Schillerstr. 5 32052 Herford GERMANY Phone: +49-5221-34606-0 Fax: +49-5221-34606-11 info@acris-antibodies.com

Synthetic Human Octreotide **Catalog No.:** PA1195 **Quantity:** 1 mg **Background:** Octreotide acetate is a longer acting synthetic octapeptide analog of naturally occurring somatostatin. It inhibits the secretion of gastro-entero-pancreatic peptide hormones and the release of growth hormone. **Species:** Human Source: Synthetic Format: State: Sterile Filtered White lyophilized (freeze-dried) powder. Purity: >98% pure as determined by RP-HPLC Buffer System: Octreotide was lyophilized from a concentrated (1.0 mg/ml) solution with no additives. **Reconstitution:** It is recommended to reconstitute the lyophilized Octreotide in sterile 18MOmega-cm H2O not less than 100 μ g/ml, which can then be further diluted to other aqueous solutions. **Description:** Synthetic Human Octreotide is a single, non-glycosylated, polypeptide chain containing 8 amino acids, having a molecular formula of C49H66N10O10S2. Octreotide is purified by proprietary chromatographic techniques. AA Sequence: H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol. Molecular weight: 1019.26 Dalton Lyophilized Octreotide although stable at room temperature, should be stored desiccated Storage: below 0°C. Reconstituted Octreotide is best stored refrigerated at 4°C. Please avoid freeze-thaw cycles. **General Readings:** 1. The role of octreotide versus placebo in the prevention of post-ERCP pancreatitis. Hepatogastroenterology 2007 Jan-Feb;54(73):250-3 2. Octreotide for esophageal variceal bleeding treated with endoscopic sclerotherapy: a randomized, placebo-controlled trial. Hepatogastroenterology 2007 Jan-Feb;54(73):195-200 3. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007 Apr;48(4):508-18 4. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology 2007 Mar;132(3):1104-16 5. Administration of octreotide for management of postoperative high-flow chylothorax. Ann Vasc Surg 2007 Jan;21(1):90-2 6. Octreotide LAR for severe obscure-overt gastrointestinal haemorrhage in high-risk

For research and in vitro use only. Not for diagnostic or therapeutic work. Material Safety Datasheets are available at www.acris-antibodies.com or on request.





OG/20121030

1/2



PA1195: Synthetic Human Octreotide

patients on anticoagulation therapy. Gut 2007 Mar;56(3):447

For research and in vitro use only. Not for diagnostic or therapeutic work. Material Safety Datasheets are available at www.acris-antibodies.com or on request. Acris Antibodies is now part of the OriGene family. Learn more at www.origene.com



OG/20121030